Medmix (MEDX) H1 2024 earnings summary

Executive summary

• Revenue for H1 2024 was CHF 241.2 million, down 2.8–3% year-over-year, but sequential growth was positive in key segments; dental and industry segments, along with the Qiaoyi acquisition, offset other declines.

• Gross margins improved slightly year-over-year and sequentially, driven by favorable product mix and dental segment recovery.

• Adjusted EBITDA margin declined 100 bps to 19.1% due to lower volumes, but reported EBITDA margin increased due to fewer extraordinary costs.

• Cash flow metrics showed strong recovery, with adjusted operating net cash flow nearly doubling to CHF 24 million and free cash flow turning positive at CHF 7.6 million.

• Leadership renewal and operational excellence initiatives were launched to drive future growth and customer centricity.

Financial highlights

• Adjusted EBITDA was CHF 46.0 million, down 7–7.4% year-over-year, with a margin of 19.1%.

• Gross profit was CHF 80.6 million, with a margin of 33.4%, up 30–35 bps year-over-year.

• Adjusted net income was CHF 18.2 million, down 24% year-over-year; net income attributable to shareholders was CHF 5.2 million, down 29.2%.

• Adjusted diluted EPS dropped to CHF 0.44 from CHF 0.58 in H1 2023.

• Net debt to adjusted EBITDA increased to 2.50x from 1.73x year-over-year.

Outlook and guidance

• Full-year 2024 guidance was revised downward: organic revenue growth now expected to be flat to negative, with adjusted EBITDA margin between 18–19%.

• H2 2024 is expected to be stronger, with Dental and Industry showing positive trends, while Drug Delivery remains under pressure.

• Efficiency improvements, operational excellence, and innovation pipeline execution are key priorities.

• Management remains optimistic about long-term growth, especially in healthcare.